Advertisement
Teva
Subscribe to Teva

The Lead

Teva to pay $1.2 billion in drug-delay settlement

May 29, 2015 11:15 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

Federal regulators announced Thursday that Teva Pharmaceuticals will pay $1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil.

Eagle Pharmaceuticals Receives Patent for Rapid Infusion Product

May 19, 2015 8:59 am | by Business Wire | News | Comments

Eagle Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office...

ANI Acquires Rights to Testosterone Gel 1%

May 13, 2015 11:31 am | by ANI Pharmaceuticals | News | Comments

ANI Pharmaceuticals has acquired the approved new drug application ("NDA") for a testosterone...

California Court Sides With Consumers in Generic Drug Fight

May 8, 2015 11:48 am | by Sudhin Thanawala, Associated Press | News | Comments

The California Supreme Court ruled that settlement agreements between pharmaceutical companies...

View Sample

FREE Email Newsletter

Mylan Launches Generic Seasonale Tablets

May 7, 2015 11:50 am | by Mylan N.V. | News | Comments

Mylan N.V. today announced the U.S. launch of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, which is the generic version of Teva's Seasonale Tablets.

Teva Announces Adrucil Recall

May 5, 2015 11:44 am | News | Comments

Teva announced a voluntary recall of eight lots of Adrucil (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) due to the potential presence of particulate matter.

FDA Approves First Generic Abilify

April 29, 2015 11:22 am | by FDA | News | Comments

The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole).

Advertisement

Teva’s Potential $40 Billion Acquisition of Mylan Could Transform Generics Space

April 24, 2015 11:26 am | by GlobalData | News | Comments

Mylan made an unsolicited $28.9 billion offer to buy the Irish drugmaker last week, but Perrigo’s board of directors unanimously rejected the proposal, saying that the merger substantially undervalues the company and its future growth prospects.

New Patent for Low-Sodium Bendamustine

April 7, 2015 12:29 pm | by Eagle Pharmaceuticals | News | Comments

Eagle Pharmaceuticals, Inc. today announced a patent for the use of bendamustine for treating patients requiring restricted fluid and/or sodium intake. 

Teva Launches Exforge Generic

March 31, 2015 11:33 am | News | Comments

Teva announces the launch of the generic equivalent to Exforge (amlodipine and valsartan) Tablets in four different strengths, in the United States.

Teva Buying Auspex for $3.2 Billion

March 30, 2015 12:54 pm | by The Associated Press | News | Comments

Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Teva Announces New Head of Business Development, Strategy and Innovation

March 23, 2015 4:05 pm | News | Comments

Teva Pharmaceutical Industries has announced the appointment of Timothy R. Wright to the Company’s executive leadership team, heading business development, strategy and innovation.

Advertisement

Teva Announces Sale of Sellersville, PA Facility

March 2, 2015 8:44 am | News | Comments

Teva Pharmaceutical Industries today announced that it has signed an agreement to sell its Sellersville, Pennsylvania facility to G&W Laboratories, Inc. This sale supports its plans to streamline operations by reducing excess manufacturing capacity and is part of the company’s previously announced cost reduction program.

FDA Accepts Teva's NDA for Abuse-Deterrent Opioid

February 25, 2015 10:03 am | News | Comments

Teva Pharmaceutical Industries announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the company’s hydrocodone bitartrate extended-release (ER) tablets formulated with Teva’s proprietary abuse deterrence technology (CEP-33237).

Watchdog Group Seeks US Ban of Antifungal Tablets

February 24, 2015 11:34 am | News | Comments

A consumer safety group is calling on the U.S Food and Drug Administration to pull certain antifungal tablets off the market, saying there are safer medicines that do not carry risks of liver damage.

FDA Approves Teva's Generic Nexium® Delayed-Release Capsules

January 27, 2015 7:06 am | News | Comments

Teva Pharmaceutical has announced the Food and Drug Administration (FDA) approval of the first generic equivalent to Nexium (esomeprazole magnesium) Delayed-Release Capsules in the United States.         

Fitch: SCOTUS Extends Patent Benefit for Teva; Generics Lose for Now

January 22, 2015 8:20 am | News | Comments

The Supreme Court (SCOTUS) decision that a federals appeals court wrongly overturned Teva Pharmaceutical's (Teva) Copaxone patent is a positive credit development for the drug maker, according to Fitch Ratings.       

Advertisement

Supreme Court Sides with Teva in Drug Dispute

January 21, 2015 8:11 am | by SAM HANANEL, Associated Press | News | Comments

The U.S. Supreme Court on Tuesday sided with Teva Pharmaceutical in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug. The justices ruled 7-2 that a federal appeals court wrongly overturned five of Teva's patents for the drug Copaxone.

OncoGenex to Regain Rights to Custirsen from Teva

January 2, 2015 8:56 am | News | Comments

OncoGenex Pharmaceuticals has executed an initial agreement with Teva Pharmaceutical Industries to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.

Teva’s GRANIX® Injection Approved for Self-Administration

December 23, 2014 8:17 am | News | Comments

Teva Pharmaceutical has announced that the FDA has approved GRANIX® Injection for self-administration by patients and caregivers. With the approval of this additional administration option, physicians will soon have the flexibility to prescribe GRANIX for either in-office or at home use.

GlobalData: Patent Cliff Means Pharmaceutical Companies Will Lose $65B by 2019

December 10, 2014 9:24 am | News | Comments

Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. The company’s report states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca, with a significant proportion of losses coming in the Central Nervous System treatment sector.

Supreme Court Weighs Generic Drug Dispute

October 15, 2014 1:28 pm | by SAM HANANEL, Associated Press | News | Comments

The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.             

Teva to Divest 14 Projects to Save $200M

October 6, 2014 8:56 am | News | Comments

Teva has identified 14 pipeline projects for discontinuation or divestment. These projects amount to more than $150 million in R&D costs in 2015 and in excess of $200 million for each of 2016 and 2017. These cost savings will be directed, in part, to increasing resources in Teva's core therapeutic areas, while another part of which will support the company's efficiency objective.

Big Cities Take Aim at Prescription Painkillers

September 16, 2014 2:25 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.      

UK High Court Gives Positive Judgment in Teva's Patent Case Against AstraZeneca

September 3, 2014 8:33 am | News | Comments

Teva Pharmaceutical announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART ( S ingle inhaler M aintenance A nd R eliever T herapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort®.

Teva Completes Acquisition of Labrys

July 21, 2014 8:15 am | News | Comments

The acquisition of Labrys brings to Teva LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), which is currently in Phase IIb clinical trials for prevention of chronic and episodic migraine.  

Arena Pharmaceuticals to Market and Supply BELVIQ in Israel

July 21, 2014 8:12 am | News | Comments

Arena Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ with Teva Pharmaceutical Industries Limited's local Israeli subsidiary, Abic Marketing Limited.

FDA Approves Expanded Label for AZILECT®

June 9, 2014 8:14 am | News | Comments

Teva Pharmaceutical Industries today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for AZILECT ® (rasagiline tablets) from monotherapy and adjunct to levodopa (LD) to now include adjunct to dopamine agonists (DAs).

Teva to Acquire Labrys Biologics

June 3, 2014 8:15 am | News | Comments

Teva will acquire Labrys for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch milestones. Potential peak sales for LBR-101 are estimated to reach $2 to $3 billion.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading